CONTACT: BECKY SOGLIN
2130 Medical Laboratories
Iowa City IA 52242
(319) 335-6660; fax (319) 335-9917
Release: June 16, 1999
UI to host international conference on prostate cancer
IOWA CITY, Iowa -- Many men and their families know
that prostate cancer is the most commonly diagnosed cancer affecting males
with an estimated 165,000 new cases this year nationwide and 1,900 new cases
in Iowa. What people may not know is that more prostate cancer research is
being conducted than ever before.
To help share those research advances, scientists
and physicians from around the world will gather June 24-27 at the University
of Iowa for its first-ever International Conference on Prostate Cancer Research.
The event, subtitled "Bridging Basic Science to the Clinic," will strengthen
connections between basic research and clinical care applications for the
disease. The UI department of urology, the UI Cancer Center, and the UI College
of Medicine are sponsoring the conference.
"We hope the conference will have an impact on sharing
knowledge of prostate cancer and how basic science can lead to clinical care
treatments," said event organizer David M. Lubaroff, Ph.D., UI professor of
urology and microbiology. Lubaroff also directs the UI Prostate Cancer Research
Program, which brings together expertise from 11 departments.
"We're planning our own UI clinical trials for prostate
cancer treatment, so it seemed like a good idea for us to organize this meeting,"
Conference participants from the United States, Europe
and Japan will attend five sessions that include lectures by leading experts
on basic science and clinical applications followed by discussion. Topics
will be prostate cancer epidemiology, prevention and control, genetic mechanisms,
research models for studying the disease, prostate tumor growth and metastasis,
and new and innovative therapies.
Presenters include James R. Cerhan, M.D., Ph.D., of
the Mayo Clinic, who as a UI faculty member in preventive medicine and environmental
health collaborated on research showing a higher incidence of prostate cancer
among Iowa farmers. In other sessions, participants will learn more about
why prostate cancer runs in some families or progresses more quickly in some
men than in others. One session will look at the use of research models such
as cell cultures, which allow researchers to conduct studies in less time
than it would take using human models. The last session will focus on treatment
"Two of the most exciting research areas in prostate
cancer treatment are gene therapy and immunotherapy," said Lubaroff, who studies
both types of potential therapies. "For example, we're looking at how you
can turn off or on genes that are associated with the cancer, and how to harness
the body's own immune system to treat the disease."
UI presenters include Lubaroff as well as Michael
B. Cohen, M.D., UI professor of pathology and urology, and director of cytopathology;
Mary J.C. Hendrix, Ph.D., UI professor and head of anatomy and cell biology,
and associate director for basic research and deputy director at the UI Cancer
Center; Timothy L. Ratliff, Ph.D., UI professor of urology; and Richard D.
Williams, M.D., professor and head of urology.
For more information, contact Deborah L. Hatz at (319)
335-8599 or firstname.lastname@example.org.